Enanta Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $15,125 | $18,314 | $14,926 | $16,959 |
Gross Profit | 15,125 | 18,314 | 14,926 | 16,959 |
EBITDA | -16,281 | -15,398 | -21,032 | -19,855 |
EBIT | -16,608 | -22,235 | -20,744 | |
Net Income | -18,700 | -18,255 | -22,644 | -22,290 |
Net Change In Cash | 15,125 | 18,314 | 14,926 | 16,959 |
Free Cash Flow | -7,947 | 17,351 | -16,026 | -25,546 |
Cash | 32,298 | 44,812 | 60,213 | 84,349 |
Basic Shares | 21,380 | 21,322 | 21,355 | 21,238 |
Annual Financials
| Values in thousands | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
Revenue | $65,324 | $67,635 | $79,204 | $86,160 |
Gross Profit | 65,324 | 67,635 | 79,204 | 86,160 |
EBITDA | -70,779 | -104,512 | -123,476 | -119,215 |
EBIT | -75,868 | -106,848 | -125,847 | -122,188 |
Net Income | -81,889 | -116,045 | -133,816 | -121,755 |
Net Change In Cash | 65,324 | 67,635 | 79,204 | 86,160 |
Cost of Revenue | -9,852 | |||
Free Cash Flow | -32,168 | -96,712 | -112,212 | -86,907 |
Cash | 32,298 | 37,233 | 85,388 | 43,994 |
Basic Shares | 21,336 | 21,157 | 20,969 | 20,603 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.87 |
2025-06-30 | -$0.85 |
2025-03-31 | -$1.06 |
